Results 11 to 20 of about 11,492 (188)
Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study
Frontiers in Immunology, 2022 BackgroundAllergic rhinoconjunctivitis (ARC) is an allergic disease that is characterized by conjunctival and nasal symptoms such as edema and congestion of conjunctiva, rhinorrhea, sneezing, and blocked nose.
Rui Tang +4 more
doaj +1 more source
Omalizumab-Associated Steatohepatitis
Actas Dermo-Sifiliográficas, 2023 Article disponible en castellà: http://hdl.handle.net/10230 ...
Barbosa, Joana +3 more
openaire +5 more sources
Dermatology Practical & Conceptual, 2022 Introduction: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. Objectives: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic ...
Irene Russo +3 more
doaj +1 more source
Clinical and Translational Allergy, 2021 Background The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended
Hanne Madsen +5 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2023 The pharmacokinetic (PK) characteristics of omalizumab and its pharmacodynamic (PD) effect in patients has yet to be fully characterized in chronic spontaneous urticaria, which could elucidate its pathogenesis and treatment response.
Elise Oh +8 more
doaj +1 more source
Roles of omalizumab in various allergic diseases
Allergology International, 2020 IgE and mast cells play a pivotal role in various allergic diseases, including asthma, allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody, has significantly improved control of these allergic diseases and ...
Yoshimichi Okayama +5 more
doaj +1 more source
World Allergy Organization Journal, 2022 Omalizumab is recommended as an add-on therapy in patients aged ≥6 years with inadequately controlled, moderate-to-severe persistent allergic asthma. The efficacy and safety of omalizumab treatment in allergic asthma clinical trials and its effectiveness
Nicola A. Hanania, MD +6 more
doaj +1 more source
Allergic bronchopulmonary aspergillosis: diagnostic and treatment challenges [PDF]
, 2016 Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder, occurring mostly in asthmatic and cystic fibrosis patients, caused by an abnormal T-helper 2 lymphocyte response of the host to Aspergillus fumigatus antigens.
CINICOLA, BIANCA LAURA +3 more
core +1 more source
Asthma referrals : a key component of asthma management that needs to be addressed [PDF]
, 2017 Peer reviewedPublisher ...
Bergen, David A +3 more
core +1 more source
Indian Journal of Dermatology, 2015 Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria.
Kiran Godse +4 more
openaire +3 more sources